Idiopathic Short Stature Clinical Trial
Official title:
Predictive Value of Baseline and Stimulated Serum IGF-1 and IGFBP-3 During a Dose-escalation IGF-1 Generation Test for the 1 Year Growth Response to Growth Hormone (GH) Therapy in Short Children With Low IGF-1 and a Normal GH Peak in a Provocation Test
Verified date | August 2019 |
Source | Ipsen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The evaluation of a standardized diagnostic test to predict the growth response in a 1 year trial with Growth Hormone (GH) treatment (carried out in the context of regular patient care) in non GH deficient short children with low serum insulin-like growth factor-1 (IGF-1).
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | May 31, 2013 |
Est. primary completion date | May 31, 2013 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 2 Years to 10 Years |
Eligibility |
Inclusion Criteria: - Age 2.0 - 9.0 years for females, 2.0 - 10.0 yrs for males. - Prepubertal stage (Tanner 1 for breast (B1) in females, or Tanner 1 for genitals (G1) for males). - Bone age < 10 'years' (males) or < 9 'years' (females) according to Greulich and Pyle. The bone age will be read by the pediatric endocrinologist responsible for the pre-study screening visit. - Height SDS < -2.5 for ethnically adequate references. For children of Dutch or Western European origin the 1997 nation-wide references for Dutch children will be used. For children of Moroccan or Turkish origin, the respective reference charts will be used. For children of other ethnicities, the 1977 North American (NCHS/WHO) reference will be used, as these charts have been accepted by WHO as world-wide standard from the age of 5 years. Exclusion Criteria: - Has a history of hypersensitivity to growth hormone or phenol (conservative added to GH in NutropinAq), or drugs with a similar chemical structure. - Has abnormal baseline findings, any other medical condition(s) or laboratory findings that, in the opinion of the Investigator, might jeopardise the subject's safety or decrease the chance of obtaining satisfactory data needed to achieve the objective(s) of the study. - Has a birth weight and/or length below -2 SDS for Swedish reference charts. Patients will not be excluded due to an unknown birth weight or length. - Has a known cause of short stature, or any significant concomitant disease that is likely to interfere with growth or with the study schedule/objectives, or is a known contraindication to GH treatment. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Ipsen |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Peak serum IGF-1 level with GH (1.4 mg/m2/day) change from baseline. | Week 2 | ||
Secondary | Delta IGF-1 SDS on 0.7 & 1.4 mg GH/m2/day | Baseline, week 2 | ||
Secondary | Delta insulin-like growth factor binding protein-3 (IGFBP-3) standard deviation score (SDS) on 0.7 & 1.4 mg GH/m2/day | Baseline, week 2 | ||
Secondary | Delta of the ratio IGF-1:IGFBP-3 SDS on 0.7 mg & 1.4 mg GH/m2/day | Baseline, week 2 | ||
Secondary | Delta of the ratio IGF-1:IGFBP-2 (insulin-like growth factor binding protein-2) SDS on 0.7 mg & 1.4 mg GH/m2/day | Baseline, week 2 | ||
Secondary | Peak IGFBP-3 SDS on 0.7 mg & 1.4 mg GH/m2/day | Baseline, week 2 | ||
Secondary | Peak of the ratio IGF-1:IGFBP-3 SDS on 0.7 mg & 1.4 mg GH/m2/day | Baseline, week 2 | ||
Secondary | Peak of the ratio IGF-1:IGFBP-2 SDS on 0.7 mg & 1.4 mg GH/m2/day | Baseline, week 2 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06382155 -
A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature
|
Phase 2 | |
Recruiting |
NCT05894876 -
A Study of the Genetic Basis of Response to Growth Hormone Treatment in Children With Idiopathic Short Stature
|
||
Completed |
NCT01246219 -
Short Stature Related Distress
|
Phase 4 | |
Completed |
NCT00965484 -
Genotropin Study Assessing Use of Injection Pen
|
Phase 3 | |
Completed |
NCT00710307 -
Epidemiology Study on Insulin-like Growth Factor-1 in Children With Idiopathic Short Stature (EPIGROW Study)
|
||
Completed |
NCT01504802 -
Pharmacodynamics of CNP During Growth Hormone Treatment
|
N/A | |
Completed |
NCT01248416 -
Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature
|
Phase 3 | |
Completed |
NCT00488124 -
Growth Response in Short Children Suffering From a Disease With Growth Retardation and Treated With Somatropin
|
Phase 2 | |
Recruiting |
NCT06309979 -
A Study to Assess Growth in Children With Idiopathic Short Stature
|
||
Terminated |
NCT00121875 -
Study to Identify Markers of Insulin Resistance During Growth Hormone Treatment for Short Stature
|
Phase 4 | |
Not yet recruiting |
NCT05858606 -
Multidisciplinary Evaluation and a Genome-wide Analysis in a Cohort of Idiopathic Short Stature Patients
|
N/A | |
Active, not recruiting |
NCT04020913 -
Skeletal Muscle Effects of GH in Boys
|
||
Completed |
NCT01401244 -
Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers
|
Phase 1 | |
Recruiting |
NCT02973061 -
The Impact of the Use of Recombinant Human Growth Hormone on ADHD Characteristics in Children and Adolescents
|
||
Completed |
NCT01778023 -
Efficacy and Safety of Recombinant Human Growth Hormone on Height Velocity in Subjects With Idiopathic Short Stature
|
Phase 3 | |
Recruiting |
NCT01604395 -
Long-term Safety and Effectiveness of Growth Hormone With GHD, TS, CRF, SGA , ISS and PWS in Children
|
||
Active, not recruiting |
NCT00840944 -
A 4 Year Combination Therapy of Growth Hormone and (GnRH) Agonist in Children With a Short Predicted Height
|
Phase 4 | |
Completed |
NCT01070173 -
Ghrelin Levels in Children With Poor Growth
|
N/A | |
Completed |
NCT01543867 -
Safety and Efficacy of Long-term Somatropin Treatment in Children
|
N/A | |
Recruiting |
NCT04798690 -
Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature
|